Skip to main content

Advertisement

SpringerLink
Log in

Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials

  • Women and Ischemic Heart Disease (J.M. Peña and F. Lin, Section Editors)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in women across all racial and ethnic groups within the USA. Despite robust evidence from randomized controlled trials demonstrating that treatment of hypercholesterolemia in women reduces cardiovascular events, women who are eligible for lipid-lowering therapy are less likely than men to be prescribed guideline-recommended therapy or to have therapy prescribed at the appropriate intensity.

Recent Findings

Historically, women have been underrepresented in clinical trials. Recent randomized clinical trials have shown that women derive similar benefits as men when treated with lipid-lowering therapy, and recent studies demonstrate potential uses for lipid-lowering therapies that extend beyond their previously well-established indications.

Summary

In this review, we will discuss lipid-lowering therapies in the context of recent clinical trials with a focus on special considerations in women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528. https://doi.org/10.1161/CIR.0000000000000659This publication quantifies important heart disease and stroke statistics.

    Article  PubMed  Google Scholar 

  2. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57(12):1404–23. https://doi.org/10.1016/j.jacc.2011.02.005.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sempos CT, Cleeman JI, Carroll MD, Johnson CL, Bachorik PS, Gordon DJ, et al. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993;269(23):3009–14. https://doi.org/10.1001/jama.269.23.3009.

    Article  CAS  PubMed  Google Scholar 

  4. Mostaghel E, Waters D. Women do benefit from lipid lowering: latest clinical trial data. Cardiol Rev. 2003;11(1):4–12. https://doi.org/10.1097/00045415-200301000-00003.

    Article  PubMed  Google Scholar 

  5. Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, et al. Sex differences in the use of statins in community practice. Circ Cardiovasc Qual Outcomes. 2019;12(8):e005562. https://doi.org/10.1161/CIRCOUTCOMES.118.005562.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Dallongevillle J, De Bacquer D, Heidrich J, De Backer G, Prugger C, Kotseva K, et al. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart. 2010;96(21):1744–9. https://doi.org/10.1136/hrt.2010.196170.

    Article  PubMed  Google Scholar 

  7. Leifheit-Limson EC, D'Onofrio G, Daneshvar M, Geda M, Bueno H, Spertus JA, et al. Sex differences in cardiac risk factors, perceived risk, and health care provider discussion of risk and risk modification among young patients with acute myocardial infarction: the VIRGO study. J Am Coll Cardiol. 2015;66(18):1949–57. https://doi.org/10.1016/j.jacc.2015.08.859.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lloyd JK. Hyperlipidaemia in children. Br Heart J. 1975;37(2):105–14. https://doi.org/10.1136/hrt.37.2.105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Freedman DS, Bowman BA, Otvos JD, Srinivasan SR, Berenson GS. Levels and correlates of LDL and VLDL particle sizes among children: the Bogalusa heart study. Atherosclerosis. 2000;152(2):441–9. https://doi.org/10.1016/s0021-9150(99)00495-5.

    Article  CAS  PubMed  Google Scholar 

  10. Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med. 1987;82(1B):54–60. https://doi.org/10.1016/0002-9343(87)90272-5.

    Article  CAS  PubMed  Google Scholar 

  11. Desoye G, Schweditsch MO, Pfeiffer KP, Zechner R, Kostner GM. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. J Clin Endocrinol Metab. 1987;64(4):704–12. https://doi.org/10.1210/jcem-64-4-704.

    Article  CAS  PubMed  Google Scholar 

  12. Fåhraeus L, Larsson-Cohn U, Wallentin L. Plasma lipoproteins including high density lipoprotein subfractions during normal pregnancy. Obstet Gynecol. 1985;66(4):468–72.

    PubMed  Google Scholar 

  13. Knopp RH, Walden CE, Wahl PW, Bergelin R, Chapman M, Irvine S, et al. Effect of postpartum lactation on lipoprotein lipids and apoproteins. J Clin Endocrinol Metab. 1985;60(3):542–7. https://doi.org/10.1210/jcem-60-3-542.

    Article  CAS  PubMed  Google Scholar 

  14. Kim ES, Menon V. Status of women in cardiovascular clinical trials. Arterioscler Thromb Vasc Biol. 2009;29(3):279–83. https://doi.org/10.1161/ATVBAHA.108.179796.

    Article  CAS  PubMed  Google Scholar 

  15. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.

    Article  CAS  PubMed  Google Scholar 

  16. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. https://doi.org/10.1056/NEJMoa1615664.

    Article  CAS  PubMed  Google Scholar 

  17. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107. https://doi.org/10.1056/NEJMoa1801174.

    Article  CAS  PubMed  Google Scholar 

  18. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. https://doi.org/10.1056/NEJMoa0807646.

    Article  CAS  PubMed  Google Scholar 

  19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9.

  20. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7. https://doi.org/10.1056/NEJM199511163332001.

    Article  CAS  PubMed  Google Scholar 

  21. Shepherd J, Breazna A, Deedwania PC, LaRosa JC, Wenger NK, Messig M, et al. Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study). Am J Cardiol. 2016;117(8):1199–205. https://doi.org/10.1016/j.amjcard.2016.01.014.

    Article  CAS  PubMed  Google Scholar 

  22. Trial AOaCftACRGTAaL-LTtPHA. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007. https://doi.org/10.1001/jama.288.23.2998.

    Article  Google Scholar 

  23. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97. https://doi.org/10.1056/NEJMoa1410489.

    Article  CAS  PubMed  Google Scholar 

  24. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–96. https://doi.org/10.1016/S0140-6736(04)16895-5.

    Article  CAS  PubMed  Google Scholar 

  25. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245–55. https://doi.org/10.1016/s0735-1097(86)80293-5.

    Article  CAS  PubMed  Google Scholar 

  26. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–45. https://doi.org/10.1056/NEJM198711123172001.

    Article  CAS  PubMed  Google Scholar 

  27. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001–9. https://doi.org/10.1056/NEJM199610033351401.

    Article  CAS  PubMed  Google Scholar 

  28. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–45. https://doi.org/10.1001/jama.294.19.2437.

    Article  CAS  PubMed  Google Scholar 

  29. Group L-TIwPiIDLS. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–57. https://doi.org/10.1056/NEJM199811053391902.

    Article  Google Scholar 

  30. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22. https://doi.org/10.1001/jama.279.20.1615.

    Article  CAS  PubMed  Google Scholar 

  31. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22. https://doi.org/10.1016/S0140-6736(02)09327-3.

    Article  Google Scholar 

  32. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504. https://doi.org/10.1056/NEJMoa040583.

    Article  CAS  PubMed  Google Scholar 

  33. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet. 1984;2(8403):600–4.

  34. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92. https://doi.org/10.1016/S0140-6736(11)60739-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30. https://doi.org/10.1016/s0140-6736(02)11600-x.

    Article  CAS  PubMed  Google Scholar 

  36. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. https://doi.org/10.1056/NEJMoa1001282.

    Article  PubMed  Google Scholar 

  37. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lespérance J. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation. 1995;92(9):2404–10. https://doi.org/10.1161/01.cir.92.9.2404.

    Article  CAS  PubMed  Google Scholar 

  38. Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405. https://doi.org/10.1016/S0140-6736(14)61368-4.

    Article  CAS  PubMed  Google Scholar 

  39. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069–77. https://doi.org/10.1161/CIRCULATIONAHA.109.906479.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA, et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017;6(11). https://doi.org/10.1161/JAHA.117.006901.

  41. Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780–8. https://doi.org/10.1001/jama.2019.16585.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–32. https://doi.org/10.1056/NEJMoa1803917.

    Article  CAS  PubMed  Google Scholar 

  43. Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662. https://doi.org/10.1161/JAHA.118.011662.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002.

    Article  CAS  PubMed  Google Scholar 

  45. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2019:2047487319864671. https://doi.org/10.1177/2047487319864671.

  46. •• Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2018, 2018:CIR0000000000000625. https://doi.org/10.1161/CIR.0000000000000625The 2018 cholesterol guidelines are the foundation upon which clinical decisions with regard to lipid lowering therapy are made.

  47. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2). https://doi.org/10.1161/CIRCOUTCOMES.116.003497.

  48. Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–76. https://doi.org/10.1001/jamacardio.2016.2415.

    Article  PubMed  Google Scholar 

  49. Roeters van Lennep JE, Heida KY, Bots ML, Hoek A, Disorders cotDMGDGoCRMaR. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(2):178–86. https://doi.org/10.1177/2047487314556004.

    Article  PubMed  Google Scholar 

  50. •• Agarwala A, Michos ED, Samad Z, Ballantyne CM, Virani SS. The use of sex-specific factors in the assessment of women's cardiovascular risk. Circulation. 2020;141(7):592–9. https://doi.org/10.1161/CIRCULATIONAHA.119.043429This primer outlines a framework for providing optimal cardiovascular care in women with sex-specific risk factors for cardioavscular disease.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab. 2004;89(8):3907–13. https://doi.org/10.1210/jc.2004-0015.

    Article  CAS  PubMed  Google Scholar 

  52. • Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(4):457–76. https://doi.org/10.1016/j.jacc.2018.10.075This document summarizes therapies for treating cardiovascular disease in women during pregnancy.

    Article  PubMed  Google Scholar 

  53. Dostal LA, Schardein JL, Anderson JA. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology. 1994;50(6):387–94. https://doi.org/10.1002/tera.1420500604.

    Article  CAS  PubMed  Google Scholar 

  54. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med. 2004;350(15):1579–82. https://doi.org/10.1056/NEJM200404083501524.

    Article  CAS  PubMed  Google Scholar 

  55. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: a systematic review. J Clin Lipidol. 2016;10(5):1081–90. https://doi.org/10.1016/j.jacl.2016.07.002.

    Article  PubMed  Google Scholar 

  56. Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, Baraldès-Farré A, Llurba E, Alijotas-Reig J. Pravastatin for preventing and treating preeclampsia: a systematic review. Obstet Gynecol Surv. 2018;73(1):40–55. https://doi.org/10.1097/OGX.0000000000000522.

    Article  PubMed  Google Scholar 

  57. Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214(6):720.e1–e17. https://doi.org/10.1016/j.ajog.2015.12.038.

    Article  CAS  Google Scholar 

  58. •• de Alwis N, Beard S, Mangwiro YT, Binder NK, Kaitu'u-Lino TJ, Brownfoot FC, et al. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction. Pregnancy Hypertens. 2020;20:83–91. https://doi.org/10.1016/j.preghy.2020.03.004This study introduces the use of pravastatin as a therapeutic agement for preventing pre-eclampsia in high risk pregnant women and demonstrates the safety of statin use during pregnancy for this indication.

    Article  PubMed  Google Scholar 

  59. Pravastatin for Prevention of Preeclampsia (Statin). ClinicalTrials.gov. Accessed 1 Feb 2021.

  60. Indonesia Pravastatin to Prevent Preeclampsia Study (INOVASIA). ClinicalTrials.gov. Accessed 1 Feb 2021.

  61. Pravastatin to Prevent Preeclampsia (Pravastatin). ClinicalTrials.gov. Accessed 1 Feb 2021.

  62. Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126(8):2933–40. https://doi.org/10.1172/JCI86957.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Botha TC, Pilcher GJ, Wolmarans K, Blom DJ, Raal FJ. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: a retrospective review of 39 pregnancies. Atherosclerosis. 2018;277:502–7. https://doi.org/10.1016/j.atherosclerosis.2018.05.038.

    Article  CAS  PubMed  Google Scholar 

  64. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S1–8. https://doi.org/10.1016/j.jacl.2011.04.003.

    Article  PubMed  Google Scholar 

  65. Study to Evaluate the Safety of Repatha in Pregnancy. ClinicalTrials.gov. Accessed 1 Feb 2021.

  66. Mehta LS, Warnes CA, Bradley E, Burton T, Economy K, Mehran R, et al. Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association. Circulation. 2020:CIR0000000000000772. https://doi.org/10.1161/CIR.0000000000000772.

  67. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(6 Suppl):S1–122.e1. https://doi.org/10.1016/j.jacl.2015.09.002.

    Article  PubMed  Google Scholar 

  68. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA. 1993;269(23):3002–8.

    Article  CAS  Google Scholar 

  69. Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1988;67(1):30–5. https://doi.org/10.1210/jcem-67-1-30.

    Article  CAS  PubMed  Google Scholar 

  70. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 1993;98(1):83–90. https://doi.org/10.1016/0021-9150(93)90225-j.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Disease, Baylor Scott and White Health Heart Hospital Baylor Plano, Plano, TX, USA

    Anandita Agarwala

  2. Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, 660 S. Euclid, Campus Box, St. Louis, MO, 8127, USA

    Anne Goldberg

Authors
  1. Anandita Agarwala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anandita Agarwala.

Ethics declarations

Conflict of Interest

A.A. declares no conflict of interest. A.G. reports grants from Pfizer; grants from Sanofi; grants and personal fees from AKCEA/IONIS; grants from Amarin; grants, personal fees, and non-financial support from Regeneron; personal fees from 23 and Me; grants from Amgen; grants and personal fees from Novartis; personal fees and non-financial support from Esperion; and personal fees from Merck, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Women and Ischemic Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Agarwala, A., Goldberg, A. Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials. Curr Atheroscler Rep 23, 42 (2021). https://doi.org/10.1007/s11883-021-00942-3

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11883-021-00942-3

Keywords

Search

Navigation